Genetic and Molecular Regulation of Neuronal Excitability in Anesthesia and Pain.
4 affiliations
- 1Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- 2Department of Biology, Duke University, Durham, NC 27708, USA.
- 3Department of Anesthesiology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
- 4Department of Anesthesiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Abstract
Genetic and molecular studies increasingly explain anesthetic and analgesic responses at the level of defined conductances, neuronal populations, and injury states. Their clinical implications depend on distinguishing target engagement from changes in firing and, ultimately, from a measurable therapeutic effect. This review examines recent evidence linking sodium, potassium, calcium, and sensory transduction channels to pain and inhibitory receptor composition, chloride regulation, and arousal circuits to anesthesia. Selective NaV1.8 inhibition provides an unusually complete translational example, spanning channel pharmacology, recordings from human sensory neurons, and randomized postoperative trials. Nevertheless, residual firing during substantial NaV1.8 inhibition and divergent explanations of NaV1.7-null analgesia show why the effects of a drug cannot be inferred directly from a genetic phenotype. Structural studies now resolve anesthetic binding and gating mechanisms in GABAA, NMDA, and HCN1 channels, while circuit experiments distinguish emergence, immobility, and antinociception. Neuroimmune signaling extends beyond cytokine-driven excitation to include inhibitory synapse removal, sex-dependent cellular pathways, and active pain resolution. Chromatin regulation, RNA modification, and neuronal senescence can stabilize altered excitability after injury. Human ganglion and spinal cord atlases, Patch-seq, and sensory assembloids provide more relevant models for connecting these mechanisms across scales, although none substitute for clinical validation. We emphasize research published from 2021 onward, retaining foundational studies where they establish a causal mechanism. The resulting evidence supports cell- and state-specific intervention rather than a single molecular explanation of anesthesia or chronic pain and identifies practical requirements for translating genetic discovery into perioperative treatment.
Related
- Divalent cation depletion enhances intrinsic neuronal excitability through CaSR-dependent modulation of threshold ion channels
- Epileptic encephalopathy-related Kv2.1 mutants impair clustering but not neuronal excitability
- Small-Conductance Ca2+-Activated K+ Channels and Their Regulation of Excitability of Autonomic Neurons
- Differential Regulation of Postoperative Gut Microbiota by Inhalation vs Intravenous Anesthesia: NF-κB/HIF-1α-Mediated Macrophage Polarization.
- Population-scale single-nucleus multi-omic profiling of skeletal muscle reveals extensive context-specific genetic regulation
BibTeX
@article{liu2026genetic,
title = {{Genetic and Molecular Regulation of Neuronal Excitability in Anesthesia and Pain.}},
author = {Zheng Liu and Tong Wang and Xinran He and Siyuan Song},
journal = {Genes},
year = {2026},
month = oct,
doi = {10.3390/genes17101283},
url = {https://europepmc.org/article/MED/42938399},
note = {CC BY},
}
RIS
TY - JOUR
TI - Genetic and Molecular Regulation of Neuronal Excitability in Anesthesia and Pain.
AU - Zheng Liu
AU - Tong Wang
AU - Xinran He
AU - Siyuan Song
PY - 2026
DA - 2026/10/15
JO - Genes
DO - 10.3390/genes17101283
UR - https://europepmc.org/article/MED/42938399
AB - Genetic and molecular studies increasingly explain anesthetic and analgesic responses at the level of defined conductances, neuronal populations, and injury states. Their clinical implications depend on distinguishing target engagement from changes in firing and, ultimately, from a measurable therapeutic effect. This review examines recent evidence linking sodium, potassium, calcium, and sensory transduction channels to pain and inhibitory receptor composition, chloride regulation, and arousal circuits to anesthesia. Selective NaV1.8 inhibition provides an unusually complete translational example, spanning channel pharmacology, recordings from human sensory neurons, and randomized postoperative trials. Nevertheless, residual firing during substantial NaV1.8 inhibition and divergent explanations of NaV1.7-null analgesia show why the effects of a drug cannot be inferred directly from a genetic phenotype. Structural studies now resolve anesthetic binding and gating mechanisms in GABAA, NMDA, and HCN1 channels, while circuit experiments distinguish emergence, immobility, and antinociception. Neuroimmune signaling extends beyond cytokine-driven excitation to include inhibitory synapse removal, sex-dependent cellular pathways, and active pain resolution. Chromatin regulation, RNA modification, and neuronal senescence can stabilize altered excitability after injury. Human ganglion and spinal cord atlases, Patch-seq, and sensory assembloids provide more relevant models for connecting these mechanisms across scales, although none substitute for clinical validation. We emphasize research published from 2021 onward, retaining foundational studies where they establish a causal mechanism. The resulting evidence supports cell- and state-specific intervention rather than a single molecular explanation of anesthesia or chronic pain and identifies practical requirements for translating genetic discovery into perioperative treatment.
SN - 2073-4425
ER -